Authors: Martha Powell, Future Science Group
Results from the Phase I trials of two vaccine approaches to Zika have been published this week, suggesting that both a gene-based vaccine and an inactivated virus vaccine are safe and immunogenic.
Gene-based approach
Results from two Phase I trials for a gene-based vaccine developed by National Institute of Allergy and Infectious Diseases (NIAID; MD, USA) have been published this week in The Lancet. NIAID has developed two plasmid-based candidates termed VRC5288 and VRC5283, both of which contain 2 genes encoding Zika proteins and are administered intramuscularly.
To view restricted content, please:
